Hydrafinil: Properties, Mechanism of Action, and Applications / Articles

Introduction

Hydrafinil (9-fluorenol) is a synthetic compound belonging to the class of eugeroics (wakefulness-promoting agents) that has attracted attention as a potential alternative to modafinil. Unlike many other stimulants, hydrafinil demonstrates a milder increase in vigilance and cognitive activity, has less effect on blood pressure and sleep, and is characterized by a lower potential for dependence. The compound is also known as 9-fluorenol, fluoren-9-ol, and 9-hydroxyfluorene. Originally patented in 1939 as an insecticide, in recent decades hydrafinil has been studied primarily in the context of cognitive stimulation and the treatment of wakefulness disorders.

Chemical Structure and Physicochemical Properties

Hydrafinil is a hydroxy derivative of fluorene — a polycyclic aromatic hydrocarbon consisting of two benzene rings connected through a central five-membered ring. The molecular formula is C₁₃H₁₀O, with a molecular weight of 182.22 g/mol.

Key physicochemical parameters:

CAS Number: 1689-64-1
Molecular formula: C₁₃H₁₀O
Molecular weight: 182.22 g/mol
Melting point: 152–155 °C
Density: 1.151 g/cm³
Solubility: practically insoluble in water (< 0.1 g/L), soluble in ethanol, acetone, DMSO
Lipophilicity (LogP): 2.4 (higher than modafinil, suggesting greater blood-brain barrier permeability)
Appearance: white to off-white crystals

Structurally, hydrafinil is fluorene with a hydroxyl group at position 9 (9-H-fluoren-9-ol). The hydroxyl group is located on the bridging carbon atom between the two benzene rings. The compound contains no chiral centers and is optically inactive.

Synthesis

Hydrafinil is typically synthesized by the reduction of 9-fluorenone using hydrogen in the presence of a nickel catalyst or using hydrazine and potassium hydroxide:

Starting material: 9-fluorenone
Reagents: H₂/Pt-Ni or hydrazine/KOH
Product: 9-fluorenol (hydrafinil)

The synthetic route is relatively straightforward and allows for the production of high-purity compound for research purposes.

Mechanism of Action

The mechanism of action of hydrafinil is multifaceted and not fully understood, but modern research identifies several key pathways.

Dopamine Transporter (DAT) Inhibition. Hydrafinil is characterized as a weak dopamine transporter (DAT) inhibitor. DAT inhibition leads to increased extracellular concentrations of dopamine — a neurotransmitter critically involved in motivation, focus, and wakefulness. Quantitative studies show that the IC₅₀ of hydrafinil for DAT is 9.0 µM, while for modafinil it is 3.70 µM. The higher IC₅₀ value corresponds to lower binding affinity, which explains hydrafinil's milder stimulatory effect compared to modafinil.

5-HT6 Receptor Antagonism (Hypothesized). Some sources suggest that hydrafinil may act as a 5-HT6 receptor antagonist. Antagonism of this receptor may lead to increased release of dopamine and norepinephrine (particularly in the prefrontal cortex), as well as glutamate and acetylcholine, which are associated with improved cognitive function, attention, and memory. However, there is conflicting information: at least one source states there is no direct evidence from binding assays to support the claim that fluorenol acts as a 5-HT6 antagonist.

Other Potential Mechanisms. Based on functional similarities to modafinil, other mechanisms have been proposed:

Histamine modulation: eugeroics such as modafinil are known to increase hypothalamic histamine levels, a key component of sleep-wake cycle regulation.
Orexin system influence: the orexin neuropeptide system is a central regulator of wakefulness.
GABAergic modulation: modafinil can decrease GABA levels in certain brain regions, potentially producing a state of disinhibition that contributes to alertness.

Pharmacokinetics

Pharmacokinetic data for hydrafinil is limited, with no formal studies detailing parameters such as bioavailability and plasma concentrations.

Half-life: approximately 6–8 hours (anecdotal)
Metabolism: Phase I (hydroxylation) and Phase II (glucuronidation, sulfo-conjugation). Metabolites have been identified in urine after a single 50 mg oral dose.
Duration of action: 4–6 hours (anecdotal), shorter than modafinil's reported 12+ hour duration.
Lipophilicity: LogP = 2.4 (higher than modafinil's 1.7), suggesting potentially greater blood-brain barrier permeability.

Clinical Applications and Research

Wakefulness Disorders. Hydrafinil has been studied for evaluating pharmacokinetics, pharmacodynamics, efficacy, tolerability, and safety for promoting wakefulness in patients with excessive sleepiness. It is being considered as an alternative for shift work and other conditions associated with sleep-wake cycle disruption.

Cognitive Enhancement. Hydrafinil is used as a nootropic agent to improve attention, memory, and fatigue resistance during mental exertion. Its mild action without pronounced euphoric effects makes it attractive for cognitive enhancement.

Dosage. Available sources recommend a dosage of 100–200 mg once daily. However, the lack of formal clinical studies makes these recommendations preliminary.

Safety and Toxicology

Safety Profile. Hydrafinil is characterized by low toxicity and a mild action profile. Possible side effects may include headache, dizziness, nausea, nervousness, anxiety, and insomnia.

Dependence Potential. Hydrafinil has a lower potential for dependence compared to modafinil, which is attributed to its weaker action at the dopamine transporter.

Doping Status. As of 2025, hydrafinil has been included by the World Anti-Doping Agency (WADA) in the group of stimulants classified as specified substances. Use of hydrafinil may lead to a positive doping test result. Athletes are advised not to use hydrafinil to enhance sports performance.

Legal Status in Russia. As of 2025, hydrafinil is not included in the list of narcotic substances and is neither prohibited nor restricted in civilian circulation. However, the compound is actively monitored by regulatory authorities in the context of anti-doping control.

Special Precautions. Because hydrafinil may cause dizziness, individuals should refrain from driving vehicles and engaging in activities requiring heightened concentration and rapid psychomotor reactions.

Storage and Handling

Hydrafinil should be stored in a dry, dark place at room temperature. For long-term storage, refrigeration is recommended. The compound is stable when stored in a dry, dark place.

Standard laboratory safety measures should be employed when handling hydrafinil: gloves, safety goggles, and work in a fume hood.

Conclusion

Hydrafinil (9-fluorenol, CAS 1689-64-1) is a promising eugeroic with mild stimulant and nootropic effects. Its mechanism of action, involving weak dopamine transporter inhibition and possibly 5-HT6 receptor antagonism, provides wakefulness promotion and cognitive enhancement without pronounced euphoric effects and with a lower potential for dependence compared to modafinil. The favorable safety profile and lack of prohibition in civilian circulation in Russia make hydrafinil an attractive subject for further research. However, the limited clinical data, inclusion in the WADA list, and the need to study long-term safety warrant a cautious approach to its use. Further research is needed to fully uncover the therapeutic potential of this compound and determine its place in clinical practice.